Author:
Raedsch R.,Plachky J.,Wolf N.,Simonis G.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference19 articles.
1. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease (1992): Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc. Dis., 2, 113–156.
2. Eisenberg S. (1990): Role of fibric acids in the management of hyperlipidemia. Curr. Opin. Lipidol., 1, 34–38.
3. Illingworth D.R. (1991): Fibric acid derivatives. In: Rifkind B.M. (ed), Drug Treatment of Hyperlipidemia. New York, Marcel Dekker, 107–131.
4. Series J.J., Caslake M.J., et al. (1988): Influence of etofibrate on low density lipoprotein metabolism. Atherosclerosis, 69, 233–239.
5. Monk J.P., Todd P.A. (1987): Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs, 33, 539–576.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献